Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.磷脂醯肌醇(PI)3-激酶抑制劑化合物,其藥學上可接受之鹽及其前體藥物;此新穎化合物之組合物,無論是單獨或併用至少一種其他治療劑,與藥學上可接受之載劑;及該新穎化合物,無論是單獨或併用至少一種其他治療劑,於預防或治療增生疾病上之用途,該疾病之特徵為生長因子、蛋白質絲胺酸/蘇胺酸激酶及磷脂激酶之異常活性。